In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Autolus Therapeutics (AUTL – Research ...

In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an ...

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...

1 Day AUTL -1.35% DJIA 1.24% Russell 2K 1.85% Health Care/Life Sciences -1.75% ...

Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) rose 5% during trading on Tuesday .The company traded as high as $2.33 and last traded at $2.32. Approximately 204,897 shares traded ...

Avanza Fonder AB bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The fund ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces ...

Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus ...